Medical - Healthcare Information Services
Compare Stocks
2 / 10Stock Comparison
SLP vs SCYX
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
SLP vs SCYX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Information Services | Drug Manufacturers - Specialty & Generic |
| Market Cap | $324M | $42M |
| Revenue (TTM) | $79M | $21M |
| Net Income (TTM) | $-64M | $-9M |
| Gross Margin | 59.6% | 9.5% |
| Operating Margin | -89.2% | -77.9% |
| Forward P/E | 18.0x | — |
| Total Debt | $616K | $2M |
| Cash & Equiv. | $31M | $21M |
SLP vs SCYX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Simulations Plus, I… (SLP) | 100 | 31.7 | -68.3% |
| SCYNEXIS, Inc. (SCYX) | 100 | 12.7 | -87.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SLP vs SCYX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SLP is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 104.0% 10Y total return vs SCYX's -97.6%
- Lower volatility, beta 1.25, Low D/E 0.5%, current ratio 7.67x
SCYX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.78
- Rev growth 449.9%, EPS growth 61.4%, 3Y rev CAGR 59.4%
- Beta 0.78, current ratio 7.04x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 449.9% revenue growth vs SLP's 13.1% | |
| Quality / Margins | -41.8% margin vs SLP's -81.7% | |
| Stability / Safety | Beta 0.78 vs SLP's 1.25 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -0.4% vs SLP's -44.6% | |
| Efficiency (ROA) | -14.4% ROA vs SLP's -46.6%, ROIC -28.2% vs -39.6% |
SLP vs SCYX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SLP vs SCYX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
SCYX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SLP is the larger business by revenue, generating $79M annually — 3.8x SCYX's $21M. SCYX is the more profitable business, keeping -41.8% of every revenue dollar as net income compared to SLP's -81.7%. On growth, SCYX holds the edge at +18.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $79M | $21M |
| EBITDAEarnings before interest/tax | -$63M | $11M |
| Net IncomeAfter-tax profit | -$64M | -$9M |
| Free Cash FlowCash after capex | $23M | -$5M |
| Gross MarginGross profit ÷ Revenue | +59.6% | +9.5% |
| Operating MarginEBIT ÷ Revenue | -89.2% | -77.9% |
| Net MarginNet income ÷ Revenue | -81.7% | -41.8% |
| FCF MarginFCF ÷ Revenue | +29.2% | -25.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.7% | +18.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.3% | +3.3% |
Valuation Metrics
SCYX leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $324M | $42M |
| Enterprise ValueMkt cap + debt − cash | $293M | $23M |
| Trailing P/EPrice ÷ TTM EPS | -4.99x | -5.63x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.01x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 4.09x | 2.02x |
| Price / BookPrice ÷ Book value/share | 2.59x | 0.97x |
| Price / FCFMarket cap ÷ FCF | 18.58x | — |
Profitability & Efficiency
Evenly matched — SLP and SCYX each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
SCYX delivers a -19.0% return on equity — every $100 of shareholder capital generates $-19 in annual profit, vs $-51 for SLP. SLP carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to SCYX's 0.04x. On the Piotroski fundamental quality scale (0–9), SLP scores 6/9 vs SCYX's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -50.5% | -19.0% |
| ROA (TTM)Return on assets | -46.6% | -14.4% |
| ROICReturn on invested capital | -39.6% | -28.2% |
| ROCEReturn on capital employed | -44.1% | -26.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.00x | 0.04x |
| Net DebtTotal debt minus cash | -$30M | -$19M |
| Cash & Equiv.Liquid assets | $31M | $21M |
| Total DebtShort + long-term debt | $616,000 | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | -20.98x |
Total Returns (Dividends Reinvested)
SLP leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SLP five years ago would be worth $2,950 today (with dividends reinvested), compared to $1,393 for SCYX. Over the past 12 months, SCYX leads with a -0.4% total return vs SLP's -44.6%. The 3-year compound annual growth rate (CAGR) favors SLP at -26.0% vs SCYX's -31.5% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -11.3% | +49.8% |
| 1-Year ReturnPast 12 months | -44.6% | -0.4% |
| 3-Year ReturnCumulative with dividends | -59.6% | -67.9% |
| 5-Year ReturnCumulative with dividends | -70.5% | -86.1% |
| 10-Year ReturnCumulative with dividends | +104.0% | -97.6% |
| CAGR (3Y)Annualised 3-year return | -26.0% | -31.5% |
Risk & Volatility
SCYX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SCYX is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than SLP's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SCYX currently trades 73.1% from its 52-week high vs SLP's 47.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 0.78x |
| 52-Week HighHighest price in past year | $34.01 | $1.31 |
| 52-Week LowLowest price in past year | $11.09 | $0.56 |
| % of 52W HighCurrent price vs 52-week peak | +47.2% | +73.1% |
| RSI (14)Momentum oscillator 0–100 | 67.9 | 51.3 |
| Avg Volume (50D)Average daily shares traded | 315K | 571K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $56.00 | — |
| # AnalystsCovering analysts | 8 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 4 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
SCYX leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). SLP leads in 1 (Total Returns). 1 tied.
SLP vs SCYX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SLP or SCYX a better buy right now?
For growth investors, SCYNEXIS, Inc.
(SCYX) is the stronger pick with 449. 9% revenue growth year-over-year, versus 13. 1% for Simulations Plus, Inc. (SLP). Analysts rate Simulations Plus, Inc. (SLP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SLP or SCYX?
Over the past 5 years, Simulations Plus, Inc.
(SLP) delivered a total return of -70. 5%, compared to -86. 1% for SCYNEXIS, Inc. (SCYX). Over 10 years, the gap is even starker: SLP returned +104. 0% versus SCYX's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SLP or SCYX?
By beta (market sensitivity over 5 years), SCYNEXIS, Inc.
(SCYX) is the lower-risk stock at 0. 78β versus Simulations Plus, Inc. 's 1. 25β — meaning SLP is approximately 59% more volatile than SCYX relative to the S&P 500. On balance sheet safety, Simulations Plus, Inc. (SLP) carries a lower debt/equity ratio of 0% versus 4% for SCYNEXIS, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SLP or SCYX?
By revenue growth (latest reported year), SCYNEXIS, Inc.
(SCYX) is pulling ahead at 449. 9% versus 13. 1% for Simulations Plus, Inc. (SLP). On earnings-per-share growth, the picture is similar: SCYNEXIS, Inc. grew EPS 61. 4% year-over-year, compared to -757. 1% for Simulations Plus, Inc.. Over a 3-year CAGR, SCYX leads at 59. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SLP or SCYX?
SCYNEXIS, Inc.
(SCYX) is the more profitable company, earning -41. 8% net margin versus -81. 7% for Simulations Plus, Inc. — meaning it keeps -41. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SCYX leads at -78. 0% versus -89. 3% for SLP. At the gross margin level — before operating expenses — SLP leads at 58. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SLP or SCYX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SLP or SCYX better for a retirement portfolio?
For long-horizon retirement investors, SCYNEXIS, Inc.
(SCYX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). Both have compounded well over 10 years (SCYX: -97. 6%, SLP: +104. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SLP and SCYX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SLP is a small-cap quality compounder stock; SCYX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.